

**IN THE SPECIFICATION:**

Page 2, lines 15-17:

Preferably, these peptide analogues have the formula (SEQ ID N<sup>o</sup> NO: 1):

Al-A2-A3-A4-A5-A6-A7-A8-Pro-Z (A)

in which:

Page 6, lines 2-6:

A preferred group of peptide analogues (A) comprises the peptides of the formula (SEQ ID N<sup>o</sup> NO: 2):

Al-His-A3-A4-A5-A6-A7-A8-Pro-Z (I)

in which:

Page 7, lines 29-32:

Among the peptide analogues of formula (I), those of the formula (SEQ ID N<sup>o</sup> NO:3):

pGlu-His-A3-Ser-A5-A6-A7-Arg-Pro-Z (II)

in which:

Page 8, lines 6-9:

Especially preferred are the peptide analogues of the formula (SEQ ID N<sup>o</sup> NO 4):

pGlu-His-A3-Ser-A5-A6-A7-Arg-Pro-Z (III)

in which:

lines 20-23:

Also especially preferred are the peptide analogues of the formula (SEQ ID N<sup>o</sup> NO 5):

pGlu-His-Trp-Ser-Tyr-A6-A7-Arg-Pro-Z (IV)

in which:

Page 8, lines 33-page 9, line 2:

Another preferred group of peptide analogues (A) comprises the peptides of the formula (SEQ ID N<sup>o</sup> NO: 6)

Al-A2-A3-A4-A5-A6-A7-A8-Pro-Z (I')

in which: